In fact, IWCLL guidelines also recommend for evaluation of TP53 aberrations and IGHV mutational status at diagnosis.1,7 Use of CLL-IPI in predicting treatment free survival (TFS) and overall survival (OS) has been validated in meta-analysis based clinical trials and few real world CLL sample sets of mainly Caucasian and East Asian in origin.8-10. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.